Allogene Therapeutics (ALLO) Appoints Shuyuan Yao as Allogene Overland Biopharm CEO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Wall Street ends down as oil prices, Treasury yields rise
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Plug Power COO resigns to join another company
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
Allogene Overland Biopharm Appoints Shuyuan Yao as Chief Executive Officer
June 21, 2021 7:00 AM EDTVeteran pharmaceutical executive with proven cell and gene therapy development experience in Asia, formerly of WuXi AppTec Shanghai and the joint venture JW Therapeutics
SOUTH SAN FRANCISCO, Calif. & BOSTON & SHANGHAI--(BUSINESS WIRE)-- Allogene Overland Biopharm (Allogene Overland), a joint venture created by Overland Pharmaceuticals and Allogene Therapeutics, Inc. (Nasdaq: ALLO), today announced the appointment of Shuyuan Yao, Ph.D. as Chief Executive Officer. Dr. Yao brings 15 years of scientific and management experience in advanced cell and gene therapy development, manufacturing and commercialization to lead Allogene... More
